2026 SARC Semiannual Meeting before ASCO |
|
|
Program: SARC Semiannual Meeting
Date: Friday, May 29, 2026
Location: Northwestern Memorial Hospital, Feinberg Pavilion, 3rd Floor; 251 E. Huron Street, Chicago, Illinois, USA
Breakfast & Networking Time: 7:30 am-9:00 am Central Time
Program Time: 9:00 am-12:00 pm Central Time Acknowledgements: SARC gratefully acknowledges our two Platinum Level Sponsors, Aadi Bioscience and Deciphera, for their generous support of the SARC Semiannual Meeting before ASCO. We are also thankful for the other supporters whose contributions help make this meeting of sarcoma stakeholders possible.
Pre-registration is required to attend the meeting. |
|
|
The BVT Early Career Travel Award |
In honor of Brian Van Tine’s legacy of mentorship, SARC has launched the BVT Early Career Travel Awards to support investigators attending key sarcoma meetings, including SASS, SASS-y, Sarcoma P31, and SARC’s Semiannual Meetings. With initial support from an anonymous donor, additional contributions are welcome to sustain this multi-year program. Click here to learn more.
|
| New Podcast: Spotlight on AYA Sarcoma |
Daphne Edgren, a Harvard MPH candidate, is launching a new podcast series as an extension of SARC’s SARC Talk, highlighting the experiences of adolescents and young adults (AYA) with sarcoma. The series debuts May 29, 2026, at the SARC Semiannual Meeting before ASCO and will be available on SARC’s website, Spotify, Apple Podcasts, and YouTube.
Click here to learn more.
|
| SARC045 Opens to Enrollment in the U.S. |
SARC045, a Phase II study of tebentafusp for HLA‑A*02:01–positive adults with advanced clear cell sarcoma, is led by Drs. Sandra D’Angelo and Andrea Napolitano. The study is now enrolling at Memorial Sloan Kettering Cancer Center and the University of Southern California; additional sites opening in the U.K. and U.S. soon.
Click here to learn more about SARC045.
|
|
|
SARC046 Opens to Enrollment |
SARC046 is now open and enrolling patients at Dana-Farber Cancer Institute. This Phase II study is evaluating nab-sirolimus in adults with progressing or symptomatic EHE, with additional U.S. sites opening soon. Click here to learn more about SARC046.
|
| SARC044 Completes Enrollment |
SARC has successfully completed patient enrollment for SARC044, a Phase II trial studying the combination of bezuclastinib and sunitinib in patients with advanced GIST who have progressed on sunitinib alone. Led by Dr. Candace Haddox. Click here to learn more about SARC044.
|
|
In Episode 33, Dr. Scott Okuno chats with Dr. Elsa Nisswandt Keeler — retired pediatrician, chondrosarcoma survivor, and dedicated advocate. They discuss her sarcoma journey, work with Rein in Sarcoma, and her new role on SARC’s Research Advocacy Council. Listen to the podcast. |
|
|
Episode 34 introduces listeners to Wendy Vanderbilt, whose extraordinary life story propels her three‑year fight against myxofibrosarcoma. She breaks down the consequences of delayed diagnosis, the urgency of self‑advocacy, and the message she believes every patient and caregiver needs to hear. Listen to the podcast.
|
|
This SARC Talk episode features Drs. Sandra D’Angelo and Andrea Napolitano discussing Clear Cell Sarcoma (CCS) and the international effort behind SARC045, a Phase II tebentafusp study for HLA‑A2–positive advanced CCS. Listen to the podcast.
|
|
In our latest SARC Talk episode, Dr. Michael Wagner, Senior Physician and Clinical Research Director at Dana-Farber Cancer Institute, shares his path into sarcoma research and his leadership of SARC046, a pivotal study of nab-sirolimus in epithelioid hemangioendothelioma (EHE). Listen to the podcast.
|
|
|
|
